- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 894787-30-5] ST2825
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-50937 |
| Brand: | MCE |
| CAS: | 894787-30-5 |
Overview
| MDL | MFCD30207830 |
|---|---|
| Molecular Weight | 591.51 |
| Molecular Formula | C27H28Cl2N4O5S |
| SMILES | O=C(N([C@H]1C(N)=O)[C@@](SCC1)([H])C2)[C@]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O |
58 Publications Citing Use of MCE
- [1]J Infect. 2019 Sep;79(3):262-276.
- [2]Gut. 2018 Nov;67(11):2035-2044.
- [3]ACS Nano. 2015 Oct 27;9(10):10498-515.
- [4]J Cachexia Sarcopenia Muscle. 2021 Nov 22.
- [5]Nat Commun. 2023 Jan 17;14(1):143.
- [6]Biomaterials. 2020 May;241:119852.
- [7]J Immunother Cancer. 2021 Dec;9(12):e003339.
- [8]Cancer Res. 2019 Mar 1;79(5):918-927.
- [9]Theranostics. 2020 Sep 15;10(25):11479-11496.
- [10]Cell Rep. 2019 Nov 26;29(9):2718-2730.e6.
- [11]Br J Pharmacol. 2015 Jun;172(12):3159-76.
- [12]J Invest Dermatol. 2019 Dec;139(12):2488-2496.e4.
- [13]Cell Death Dis. 2022 Apr 28;13(4):411.
- [14]Cell Death Dis. 2021 May 12;12(5):477.
- [15]Acta Neuropathol Commun. 2020 Aug 13;8(1):135.
- [16]J Pathol. 2022 Apr;256(4):414-426.
- [17]J Neuroinflammation. 2018 Mar 19;15(1):87.
- [18]Emerg Microbes Infect. Jan-Feb 2021;23(1):104765.
- [19]J Cell Physiol. 2019 May;234(5):7645-7658.
- [20]Int J Biol Macromol. 2021 Apr 24.
- [21]Int J Biol Macromol. 2018 May;111:813-821.
- [22]Oxid Med Cell Longev. 2018 Jun 26;2018:2917981.
- [23]FASEB J. 2021 Oct;35(10):e21820.
- [24]Front Oncol. 2020 Sep 18;10:1780.
- [25]Exp Neurol. 2017 Sep;295:23-35.
- [26]Food Chem Toxicol. 2022 Aug 30;113400.
- [27]Eur J Immunol. 2020 Sep;50(9):1350-1361.
- [28]Bone. 2022 Jan 5;116324.
- [29]Sci Rep. 2017 Nov 17;7(1):15797.
- [30]Sci Rep. 2017 Mar 17;7:44822.
- [31]Int Immunopharmacol. 2018 Aug 22;64:33-41.
- [32]PLoS Negl Trop Dis. 2018 Dec 27;12(12):e0007000.
- [33]Mediat Inflamm. 21 Dec 2021.
- [34]Oncol Rep. 2019 Nov;42(5):1755-1766.
- [35]Dev Dyn. 2021 Apr 1.
- [36]Molecules. 2022 May 6;27(9):2990.
- [37]Molecules. 2018 Oct 16;23(10). pii: E2658.
- [38]Inflammopharmacology. 2019 Dec;27(6):1143-1153.
- [39]Vet Microbiol. 2019 Aug;235:53-62.
- [40]J Inflamm. 2022 Dec 30;19(1):28.
- [41]PLoS One. 2014 Jul 18;9(7):e100985.
- [42]Brain Res. 2016 Jul 15;1643:130-9.
- [43]Mycopathologia. 2021 Jun 4.
- [44]Oncol Lett. 2018 Oct;16(4):4929-4936.
- [45]Oncol Lett. 2018 Jun;15(6):9647-9654.
- [46]Neurosci Lett. 28 November 2021, 136374.
- [47]Mol Med Rep. 2015 Jul;12(1):895-904.
- [48]Theriogenology. 2020 Aug;152:129-138.
- [49]Theriogenology. 2018 Oct 1;119:80-90.
- [50]Anticancer Res. 2017 Nov;37(11):6203-6209.
- [51]Eur J Inflamm. May 16, 2022.
- [52]Research Square Preprint. 2021 Nov.
- [53]Technischen Universität Dresden. Department of Chemistry. 04 Oct 2021.
- [54]Research Square Preprint. 2020 Jun.
- [55]bioRxiv. 2020 Apr.
- [56]Department of Microbiology and Immunology. Indiana University. 2018 May.
- [57]Genet Mol Res. 2016 Mar 4;15(1):15016826.
- [58]Journal of China Medical University. 2015 Jun; 44(6): 562-564.
Summary
IC50 & Target
MyD88 [1]
In Vitro
ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 169.06 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6906 mL | 8.4529 mL | 16.9059 mL |
| 5 mM | 0.3381 mL | 1.6906 mL | 3.3812 mL |
| 10 mM | 0.1691 mL | 0.8453 mL | 1.6906 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.23 mM); Clear solution
References
- [1] Loiarro M, et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10.
- [2] Fantò N, et al. Design, Synthesis, and In Vitro Activity of Peptidomimetic Inhibitors of Myeloid Differentiation Factor 88. J Med Chem. 2008 Mar 13;51(5):1189-202.
- [3] Van Tassell BW, et al. Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse. J Cardiovasc Pharmacol. 2010 Apr;55(4):385-90.
- [4] Zhang HS, et al. Inhibition of myeloid differentiation factor 88(MyD88) by ST2825 provides neuroprotection after experimental traumatic brain injury in mice. Brain Res. 2016 Jul 15;1643:130-9.
- [5] Wang N, et al. Myeloid differentiation factor 88 is up-regulated in epileptic brain and contributes to experimental seizures in rats. Exp Neurol. 2017 Sep;295:23-35.
- [6] Brad Griesenauer, et al. ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function. Indiana University. May 2018.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.